The Development of Biosimilars for a Range of Recombinant Protein Classes is Becoming Increasingly Attractive According to New Research Report

Business Wire, August 23, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c66404) has announced the addition of "Biosimilars: Benchmarking the Key Players - With Increasing Regulatory Clarity and High Revenue Potential, Interest in Biosimilars Increases" to their offering.

With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.

Scope of this title:

* Overview of the biosimilars competitive landscape, examining how the key players dominate the environment

* Update of in-depth profiles of the top-12 biosimilar developers

* Identification of licensing and collaboration trends shaping the biosimilars environment

* Analysis of biosimilar development trends in terms of target protein class, drug delivery and reformulation technology, and geographical launch market

Highlights of this title:

* Well-established generics companies such as Sandoz and Teva have led the drive into the biosimilars market, by launching across a range of emerging and Western markets in a small number of well-characterized and relatively simple recombinant protein classes with significant market potential.

* Although established generics companies have so far dominated the biosimilars landscape, emerging biosimilar developers have the greatest number of disclosed pipeline biosimilar programs, which are set to broaden the range of biosimilars being developed in terms of protein class, drug delivery and formulation.

* There has been significant licensing and M&A deal activity among the top-12 biosimilar companies, enabling them to build a stronger product portfolio and gain greater access to capabilities that are key to competing in this market, such as drug delivery (primarily advanced injection technology) and drug formulation (mainly pegylation) technologies.

Reasons to order your copy:

* Evaluate the competitive landscape of the top-12 biosimilar developers

* Identify the trends shaping biosimilar product development among the top-12 biosimilar developers

* Understand the drivers for licensing and M&A deals being conducted by the top-12 biosimilar developers

Contents:

Chapter 1.
Executive summary
Scope of the report
Key findings
Key definitions

Chapter 2.
Review of key biosimilar developers' portfolio and pipeline
Introduction
Future launches are expected to increase the diversity of the
 biosimilar market
Human growth hormone dominates the therapeutic focus of
 currently-marketed biosimilars
Pipeline biosimilars are targeting an increased number of recombinant
 protein classes
Biosimilar developers are turning to a range of drug delivery and
 formulation technologies to differentiate their products from
 competitors
Innovative injection devices dominate advanced biosimilar drug
 delivery
Improving biosimilar pharmacodynamics using pegylation-like
 technologies dominates advanced biosimilar drug reformulation
Biosimilar developers deprioritize emerging markets and focus pipeline
 launches on Western markets to maximize profit

Chapter 3.
Collaboration and m&a trends in the biosimilars market
There are a wide range of drivers powering licensing and M&A deals
Deals are used extensively in the biosimilars market to enable
 biosimilars to penetrate new markets
Top-12 biosimilar developers use M&A deals over licensing deals to
 access emerging markets
Both M&A deals and licensing deals are used by biosimilar developers
 to access Western markets
The core focus for licensing deals is to source marketed and/or
 pipeline products
Much licensing and M&A activity focuses on improving market access or
 putting up barriers for competitors
Biosimilar manufacturers use licensing deals rather than M&A deals to
 gain access to reformulation and/or drug delivery technologies
Deals can also be used to provide a biosimilar with a larger
 specialist sales force to remove barriers to entry and improve
 market access

Chapter 4.
Biosimilar company profiles
Key biosimilar companies profiled
Leading biosimilar developers
Teva (and its subsidiary SICOR)
Sandoz
Barr (through acquisition of Pliva)
Stada (through Bioceuticals)
BioPartners
BioGeneriX (ratiopharm group)
New, smaller biosimilar-focused companies
Cangene
Hospira
Phage Biotechnology
Dragon Pharmaceutical
Neose Technologies
GeneMedix
Emerging market-based biosimilar developers and very early-stage
 companies
Indian biosimilars players
Chinese biosimilars players
Very early-stage biosimilars companies

For more information visit http://www.researchandmarkets.com/reports/c66404

Source: Datamonitor